In the last trading session, 1.23 million VYNE Therapeutics Inc (NASDAQ:VYNE) shares changed hands as the company’s beta touched 1.72. With the company’s per share price at $1.42 changed hands at -$0.2 or -12.35% during last session, the market valuation stood at $23.66M. VYNE’s last price was a discount, traded about -202.82% off its 52-week high of $4.30. The share price had its 52-week low at $0.85, which suggests the last value was 40.14% up since then. When we look at VYNE Therapeutics Inc’s average trading volume, we note the 10-day average is 1.61 million shares, with the 3-month average coming to 454.94K.
Analysts gave the VYNE Therapeutics Inc (VYNE) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.00. If we narrow down to specifics, the data shows that 0 out of 1 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended VYNE as a Hold, 1 felt it is a Buy and 0 rated the stock as Underweight.
VYNE Therapeutics Inc (NASDAQ:VYNE) trade information
Instantly VYNE was in red as seen at the end of in last trading. With action 59.55%, the performance over the past five days has been green. The company’s shares are showing year-to-date downside of -17.92%, with the 5-day performance at 59.55% in the green. However, in the 30-day time frame, VYNE Therapeutics Inc (NASDAQ:VYNE) is 45.64% up. Looking at the short shares, we see there were 0.34 million shares sold at short interest cover period of 1.08 days.
The consensus price target for the stock as assigned by Wall Street analysts is 5.75, meaning bulls need an upside of 75.3% from its current market value. According to analyst projections, VYNE’s forecast low is 5.75 with 5.75 as the target high. To hit the forecast high, the stock’s price needs a -304.93% plunge from its current level, while the stock would need to soar -304.93% for it to hit the projected low.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 65.87%. The 2025 estimates are for VYNE Therapeutics Inc earnings to decrease by -13.62%, but the outlook for the next 5-year period is at 11.71% per year.
VYNE Dividends
VYNE Therapeutics Inc is expected to release its next quarterly earnings report on 2025-May-08.
VYNE Therapeutics Inc (NASDAQ:VYNE)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 8.34% of VYNE Therapeutics Inc shares while 47.62% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 51.96%. There are 47.62% institutions holding the VYNE Therapeutics Inc stock share, with EVENTIDE ASSET MANAGEMENT, LLC the top institutional holder. As of 2024-06-30, the company held 3.2742% of the shares, roughly 1.39 million VYNE shares worth $3.13 million.
CORMORANT ASSET MANAGEMENT, LP holds the second largest percentage of outstanding shares, with 3.2742% or 1.39 million shares worth $2.75 million as of 2024-06-30.
